Transplant outcomes after intensive chemotherapy or venetoclax plus azacitidine in acute myeloid leukemia: a multicenter retrospective study in Japan. [PDF]
Muranushi H +25 more
europepmc +1 more source
Computational insights into synergistic mechanisms of PD-901 and 5-azacitidine targeting PTPN11 (SHP2) E76K mutation in juvenile myelomonocytic leukemia. [PDF]
Al-Subaie AM, Kamaraj B.
europepmc +1 more source
FLT3-mutated AML: standards of care and ongoing investigation. [PDF]
Do LV, Jorgensen JJ, Sahasrabudhe KD.
europepmc +1 more source
Wired to Survive: How AML Cytogenetics Shape Apoptotic Dependence and Venetoclax Resistance. [PDF]
Rojas A +3 more
europepmc +1 more source
Gastrointestinal adverse reactions and metabolism-nutrition disorders associated with hypomethylating agents: a pharmacovigilance study with exploratory mechanistic analysis. [PDF]
Xiang M +8 more
europepmc +1 more source
Azacitidine-Venetoclax in Elderly and Unfit Acute Myeloid Leukemia: Real-World Outcomes Outside Clinical Trials. [PDF]
Fazio M +11 more
europepmc +1 more source
Controversies in the Management of AML in Older Patients: A Canadian Perspective. [PDF]
Schuh AC +4 more
europepmc +1 more source
Vexas Syndrome: A Multisystem Challenge with Sweet Syndrome and Myelodysplastic Syndrome. [PDF]
Kouli A +6 more
europepmc +1 more source
Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML. [PDF]
Arvidsson Kvissberg M +8 more
europepmc +1 more source
Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML. [PDF]
Romero-Murillo S +15 more
europepmc +1 more source

